Navoximod

• CAT Number: I001543
• CAS Number: 1402837-78-8
• Molecular Formula: C18H21FN2O2
• Molecular Weight: 316.3764
• Purity: ≥95%
• Synonyms: Navoximod; IDO-IN-7; IDOIN7; IDO IN 7; 1793075-63-4 (phosphate); 1402837-78-8 (free base); Navoximod Phosphate;(1R,4r)-4-((R)-2-((S)-6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol
• Target: Indoleamine 2,3-Dioxygenase (IDO)
• Solubility: Soluble in DMSO
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• InChI: 1S/C18H21FN2O2/c19-14-3-1-2-13-16-9-20-10-21(16)15(18(13)14)8-17(23)11-4-6-12(22)7-5-11/h1-3,9-12,15,17,22-23H,4-8H2/t11-,12-,15-,17+/m0/s1
• SMILES: O[C@@H]([C@H]1CC[C@H](O)CC1)C[C@@H](C2=C3C=CC=C2F)N4C3=CN=C4

Navoximod (CAT: I001543), also known as IDO-IN-7, is a potent inhibitor of indoleamine 2,3-dioxygenase (IDO). IDO is an enzyme involved in the catabolism of the amino acid tryptophan, and its inhibition can modulate immune responses. Navoximod acts as an immunomodulator by blocking the activity of IDO, which is responsible for suppressing T-cell immune responses. This inhibition can enhance the immune system’s ability to recognize and attack tumor cells. As an antineoplastic agent, navoximod shows potential in the treatment of various cancers by targeting the IDO pathway and promoting an anti-tumor immune response.

Reference

[1]. Mautino, et al. Preparation of fused imidazole derivatives as IDO inhibitors. From PCT Int. Appl. (2012), 20121018.